ACT-1 A PROSPECTIVE MULTICENTER PHASE I/IIA STUDY OF PREOPERATIVE NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED GLIOBLASTOMA

MLA

Toshihide Tanaka, et al. “Act-1 a Prospective Multicenter Phase I/Iia Study of Preoperative Neoadjuvant Bevacizumab for Newly Diagnosed Glioblastoma.” Neuro-Oncology Advances, vol. 4, Dec. 2022, p. iii7. EBSCOhost, https://doi.org/10.1093/noajnl/vdac167.025.

APA

Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotarou Imai, Yohei Yamamoto, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, & Hikaru Sasaki. (2022). Act-1 a Prospective Multicenter Phase I/Iia Study of Preoperative Neoadjuvant Bevacizumab for Newly Diagnosed Glioblastoma. Neuro-Oncology Advances, 4, iii7. https://doi.org/10.1093/noajnl/vdac167.025

Chicago

Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, et al. 2022. “Act-1 a Prospective Multicenter Phase I/Iia Study of Preoperative Neoadjuvant Bevacizumab for Newly Diagnosed Glioblastoma.” Neuro-Oncology Advances 4 (December): iii7. doi:10.1093/noajnl/vdac167.025.